Interaction Checker

Dasatinib etkileşimleri

Dasatinib (Sprycel, Phyrago) için dizinlediğimiz FDA etiketlerinde ve bilgi sayfalarında 152 belgelenmiş etkileşim var: 69 majör, 30 orta, 53 minör ve bir etiketin anlamlı etkileşim olmadığını bildirdiği 0 çift. Aşağıdaki her kayıt, dayandığı cümleyi alıntılar. Bu ilaç sayfası bir başlangıç noktasıdır; sizin durumunuz için verilmiş bir hüküm değildir.

Etikete göre etkileşimler

Majör etkileşimler (69)

  • AmiodaronantiaritmikMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • Antasitler (Tums, Maalox, Mylanta)Reçetesiz ürünMajör

    Antacids: Avoid concomitant use. (Dasatinib etiketi, İlaç etkileşimleri)

  • AprepitantCYP3A4 inhibitörüMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • ArmodafinilMSS uyarıcısıMajör

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib etiketi, İlaç etkileşimleri)

  • AtazanavirantiretroviralMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • BosentanCYP3A4 indükleyicisiMajör

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib etiketi, İlaç etkileşimleri)

  • DarunavirantiretroviralMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • Darunavir ve kobisistatantiretroviralMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • Deferasiroksdemir takviyesiMajör

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib etiketi, İlaç etkileşimleri)

  • DeksametazonkortikosteroidMajör

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib etiketi, İlaç etkileşimleri)

  • Diltiazemkalsiyum kanal blokeriMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • DronedaronantiaritmikMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • EfavirenzantiretroviralMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • Efavirenz, lamivudin ve tenofovirantiretroviralMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • Elvitegravir, kobisistat, emtrisitabin ve tenofovirantiretroviralMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • Eritromisinmakrolid antibiyotikMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • EslikarbazepinantikonvülsanMajör

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib etiketi, İlaç etkileşimleri)

  • EtravirinantiretroviralMajör

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib etiketi, İlaç etkileşimleri)

  • EverolimusimmünosüpresanMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • FenitoinantikonvülsanMajör

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib etiketi, İlaç etkileşimleri)

  • FenobarbitalbarbitüratMajör

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib etiketi, İlaç etkileşimleri)

  • Fentermin ve topiramatMSS uyarıcısıMajör

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib etiketi, İlaç etkileşimleri)

  • Flukonazolazol antifungalMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • FosamprenavirantiretroviralMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • FosaprepitantCYP3A4 inhibitörüMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • FosfenitoinantikonvülsanMajör

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib etiketi, İlaç etkileşimleri)

  • GriseofulvinantifungalMajör

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib etiketi, İlaç etkileşimleri)

  • İbuprofen ve famotidinNSAİİMajör

    Intervention Concomitant administration of ibuprofen and famotidine tablet is not recommended with dasatinib, delavirdine mesylate, cefditoren, and fosamprenavir. (İbuprofen ve famotidin etiketi, İlaç etkileşimleri)

  • İmatinibCYP3A4 inhibitörüMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • İtrakonazolazol antifungalMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • İvakaftorCYP3A4 inhibitörüMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • İzoniazidantibiyotikMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • KarbamazepinantikonvülsanMajör

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib etiketi, İlaç etkileşimleri)

  • Ketokonazolazol antifungalMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • Klaritromisinmakrolid antibiyotikMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • KlobazambenzodiazepinMajör

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib etiketi, İlaç etkileşimleri)

  • LenakapavirantiretroviralMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • Lopinavir ve ritonavirantiretroviralMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • LorlatinibCYP3A4 indükleyicisiMajör

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib etiketi, İlaç etkileşimleri)

  • MifepristonCYP3A4 inhibitörüMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • Mirabegronbeta adrenerjik agonistMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • MitapivatCYP3A4 indükleyicisiMajör

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib etiketi, İlaç etkileşimleri)

  • MitotanCYP3A4 indükleyicisiMajör

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib etiketi, İlaç etkileşimleri)

  • ModafinilMSS uyarıcısıMajör

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib etiketi, İlaç etkileşimleri)

  • Nafsilinpenisilin antibiyotikMajör

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib etiketi, İlaç etkileşimleri)

  • NefazodonantidepresanMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • NevirapinantiretroviralMajör

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib etiketi, İlaç etkileşimleri)

  • Nirmatrelvir ve ritonavirantiviralMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • OkskarbazepinantikonvülsanMajör

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib etiketi, İlaç etkileşimleri)

  • Omeprazol ve sodyum bikarbonatproton pompası inhibitörüMajör

    Antacids: Avoid concomitant use. (Dasatinib etiketi, İlaç etkileşimleri)

  • PalbosiklibCYP3A4 inhibitörüMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • PerampanelantikonvülsanMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • Posakonazolazol antifungalMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • PrimidonantikonvülsanMajör

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib etiketi, İlaç etkileşimleri)

  • RanolazinQT aralığını uzatan ilaçMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • RifabutinantibiyotikMajör

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib etiketi, İlaç etkileşimleri)

  • RifampisinantibiyotikMajör

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib etiketi, İlaç etkileşimleri)

  • RifapentinantibiyotikMajör

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib etiketi, İlaç etkileşimleri)

  • RitonavirantiretroviralMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • SenobamatantikonvülsanMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • SiklosporinimmünosüpresanMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • SimetidinH2 blokeriMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • Sodyum bikarbonatantasitMajör

    Antacids: Avoid concomitant use. (Dasatinib etiketi, İlaç etkileşimleri)

  • Suvoreksantsedatif-hipnotikMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • SuzetrijinCYP3A4 indükleyicisiMajör

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib etiketi, İlaç etkileşimleri)

  • Tikagrelorantitrombosit ilaçMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • TopiramatantikonvülsanMajör

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib etiketi, İlaç etkileşimleri)

  • Verapamilkalsiyum kanal blokeriMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

  • Vorikonazolazol antifungalMajör

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

Orta düzey etkileşimler (30)

  • AdenozinantiaritmikOrta

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Dasatinib etiketi, Uyarılar ve önlemler)

  • ApiksabanantikoagülanOrta

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (Dasatinib etiketi, Uyarılar ve önlemler)

  • ArgatrobanantikoagülanOrta

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (Dasatinib etiketi, Uyarılar ve önlemler)

  • BivalirudinantikoagülanOrta

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (Dasatinib etiketi, Uyarılar ve önlemler)

  • DabigatranantikoagülanOrta

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (Dasatinib etiketi, Uyarılar ve önlemler)

  • Dekslansoprazolproton pompası inhibitörüOrta

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Dexlansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (Dekslansoprazol etiketi, İlaç etkileşimleri)

  • Digoksindijital glikozidiOrta

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Dasatinib etiketi, Uyarılar ve önlemler)

  • DisopiramidantiaritmikOrta

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Dasatinib etiketi, Uyarılar ve önlemler)

  • DofetilidantiaritmikOrta

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Dasatinib etiketi, Uyarılar ve önlemler)

  • EdoksabanantikoagülanOrta

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (Dasatinib etiketi, Uyarılar ve önlemler)

  • EnoksaparinantikoagülanOrta

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (Dasatinib etiketi, Uyarılar ve önlemler)

  • Esmololbeta blokerOrta

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Dasatinib etiketi, Uyarılar ve önlemler)

  • Esomeprazolproton pompası inhibitörüOrta

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole… (Esomeprazol etiketi, İlaç etkileşimleri)

  • FlekainidantiaritmikOrta

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Dasatinib etiketi, Uyarılar ve önlemler)

  • FondaparinuksantikoagülanOrta

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (Dasatinib etiketi, Uyarılar ve önlemler)

  • HeparinantikoagülanOrta

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (Dasatinib etiketi, Uyarılar ve önlemler)

  • İbutilidantiaritmikOrta

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Dasatinib etiketi, Uyarılar ve önlemler)

  • KinidinantiaritmikOrta

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Dasatinib etiketi, Uyarılar ve önlemler)

  • Lansoprazolproton pompası inhibitörüOrta

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Lansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (Lansoprazol etiketi, İlaç etkileşimleri)

  • Lidokainlokal anestezikOrta

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Dasatinib etiketi, Uyarılar ve önlemler)

  • Lidokain ve prilokainlokal anestezikOrta

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Dasatinib etiketi, Uyarılar ve önlemler)

  • MeksiletinantiaritmikOrta

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Dasatinib etiketi, Uyarılar ve önlemler)

  • Omeprazolproton pompası inhibitörüOrta

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (Omeprazol etiketi, İlaç etkileşimleri)

  • Pantoprazolproton pompası inhibitörüOrta

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (Pantoprazol etiketi, İlaç etkileşimleri)

  • ProkainamidantiaritmikOrta

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Dasatinib etiketi, Uyarılar ve önlemler)

  • PropafenonantiaritmikOrta

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Dasatinib etiketi, Uyarılar ve önlemler)

  • Rabeprazolproton pompası inhibitörüOrta

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole, itraconazole) Clinical Impact: Rabeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (Rabeprazol etiketi, İlaç etkileşimleri)

  • RivaroksabanantikoagülanOrta

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (Dasatinib etiketi, Uyarılar ve önlemler)

  • Sotalolbeta blokerOrta

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Dasatinib etiketi, Uyarılar ve önlemler)

  • VarfarinantikoagülanOrta

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (Dasatinib etiketi, Uyarılar ve önlemler)

Minör değinmeler (53)

  • Amiloridpotasyum tutucu diüretikMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • Asetazolamidkarbonik anhidraz inhibitörüMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • Atenolol ve klortalidonbeta blokerMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • Azelastin ve flutikazonantihistaminikMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • BeklometazonkortikosteroidMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • Benazepril ve hidroklorotiyazidACE inhibitörüMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • BetametazonkortikosteroidMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • Bisoprolol ve hidroklorotiyazidbeta blokerMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • BudesonidkortikosteroidMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • Budesonid ve formoterolkortikosteroidMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • Bumetanidkıvrım (loop) diüretiğiMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • DeflazakortkortikosteroidMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • DesonidkortikosteroidMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • Enalapril ve hidroklorotiyazidACE inhibitörüMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • Eplerenonaldosteron antagonistiMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • Etakrinik asitkıvrım (loop) diüretiğiMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • FludrokortizonkortikosteroidMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • FlunisolidkortikosteroidMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • FluosinonidkortikosteroidMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • FlutikazonkortikosteroidMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • Flutikazon ve salmeterolkortikosteroidMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • Fosinopril ve hidroklorotiyazidACE inhibitörüMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • Furosemidkıvrım (loop) diüretiğiMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • HalobetazolkortikosteroidMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • Hidroklorotiyazidtiyazid diüretikMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • HidrokortizonkortikosteroidMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • İndapamidtiyazid diüretikMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • İrbesartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Minör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • Kandesartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Minör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • Kinapril ve hidroklorotiyazidACE inhibitörüMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • KlobetazolkortikosteroidMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • Klorotiyazidtiyazid diüretikMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • Klortalidontiyazid diüretikMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • Lisinopril ve hidroklorotiyazidACE inhibitörüMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • Losartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Minör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • MetilprednizolonkortikosteroidMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • Metolazontiyazid diüretikMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • Metoprolol ve hidroklorotiyazidbeta blokerMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • MometazonkortikosteroidMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • Olmesartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Minör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • Olmesartan, amlodipin ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Minör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • Olopatadin ve mometazonantihistaminikMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • PrednizolonkortikosteroidMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • PrednizonkortikosteroidMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • SiklesonidkortikosteroidMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • Spironolaktonaldosteron antagonistiMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • Spironolakton ve hidroklorotiyazidaldosteron antagonistiMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • Telmisartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Minör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • Torasemidkıvrım (loop) diüretiğiMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • TriamsinolonkortikosteroidMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • Triamterenpotasyum tutucu diüretikMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • Triamteren ve hidroklorotiyazidpotasyum tutucu diüretikMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • Valsartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Minör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

Kullandığınız her şeyi Dasatinib ile karşılaştırın. Tüm listenizi ekleyin; her çift tek seferde kontrol edilir.

Sorgulama aracında aç

Tıbbi tavsiye değildir. Şiddet derecesi sizin koşullarınızı değil, etiketin ifadesini yansıtır. “Majör” işareti gözetim altında olağan bir uygulama olabilir, “minör” işareti ise yüksek dozlarda önem kazanabilir. Bir eczacıya danışın.